Success Metrics

Clinical Success Rate
90.2%

Based on 46 completed trials

Completion Rate
90%(46/51)
Active Trials
3(5%)
Results Posted
80%(37 trials)
Terminated
5(8%)

Phase Distribution

Ph phase_1
7
11%
Ph phase_2
10
16%
Ph phase_3
32
51%
Ph not_applicable
2
3%
Ph phase_4
8
13%

Phase Distribution

7

Early Stage

10

Mid Stage

40

Late Stage

Phase Distribution59 total trials
Phase 1Safety & dosage
7(11.9%)
Phase 2Efficacy & side effects
10(16.9%)
Phase 3Large-scale testing
32(54.2%)
Phase 4Post-market surveillance
8(13.6%)
N/ANon-phased studies
2(3.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.2%

46 of 54 finished

Non-Completion Rate

14.8%

8 ended early

Currently Active

3

trials recruiting

Total Trials

63

all time

Status Distribution
Active(3)
Completed(46)
Terminated(8)
Other(6)

Detailed Status

Completed46
unknown6
Terminated5
Withdrawn3
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
63
Active
3
Success Rate
90.2%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (11.9%)
Phase 210 (16.9%)
Phase 332 (54.2%)
Phase 48 (13.6%)
N/A2 (3.4%)

Trials by Status

withdrawn35%
terminated58%
recruiting23%
active_not_recruiting12%
unknown610%
completed4673%

Recent Activity

Clinical Trials (63)

Showing 20 of 63 trialsScroll for more
NCT04123795Phase 3

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

Active Not Recruiting
NCT03152058Phase 2

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Recruiting
NCT07491913Not Applicable

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

Recruiting
NCT03559660

CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

Unknown
NCT03559686

Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)

Unknown
NCT04740814Phase 1

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Completed
NCT03215277Phase 2

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Completed
NCT04053881

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

Completed
NCT04610476Phase 3

Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Unknown
NCT03100253Phase 4

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

Terminated
NCT02552212Phase 3

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Completed
NCT01197066Phase 3

Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

Completed
NCT03051217Phase 2

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Completed
NCT02346240Phase 3

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Completed
NCT04643483Phase 3

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

Withdrawn
NCT03020992Phase 4

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

Completed
NCT01190410Phase 2

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

Completed
NCT02505542Phase 3

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

Completed
NCT00160602Phase 3

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Completed
NCT00291668Phase 2

Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

Completed

Drug Details

Intervention Type
DRUG
Total Trials
63